Loading...
XKRX
207940
Market cap48bUSD
Mar 31, Last price  
1,014,000.00KRW
1D
-3.34%
1Q
6.85%
Jan 2017
571.52%
IPO
527.86%
Name

Samsung Biologics Co Ltd

Chart & Performance

D1W1MN
P/E
66.62
P/S
15.87
EPS
15,220.67
Div Yield, %
—
Shrs. gr., 5y
1.26%
Rev. gr., 5y
45.32%
Revenues
4.55t
+23.08%
105,148,783,57091,278,028,790294,622,020,770464,629,334,140535,805,801,070701,591,859,7601,164,776,873,6401,568,006,928,0403,001,295,197,6803,694,588,767,0604,547,322,176,420
Net income
1.08t
+26.31%
-95,909,287,8101,904,945,916,600-176,823,409,530-96,972,115,810224,109,194,870202,904,099,090240,974,799,960393,589,467,650798,056,210,080857,691,298,3801,083,315,885,980
CFO
1.66t
-0.42%
-108,299,232,940-265,513,751,570-62,661,298,030149,816,327,600-32,417,327,33010,153,614,980202,090,026,540454,596,217,270953,047,810,0801,666,228,521,4401,659,255,402,660
Earnings
Apr 22, 2025

Profile

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
URL
https://samsungbiologics.com/
IPO date
Nov 10, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,547,322,176
23.08%
3,694,588,767
23.10%
3,001,295,198
91.41%
Cost of revenue
2,877,818,758
2,285,202,032
1,788,220,999
Unusual Expense (Income)
NOPBT
1,669,503,418
1,409,386,735
1,213,074,199
NOPBT Margin
36.71%
38.15%
40.42%
Operating Taxes
286,735,740
262,295,633
210,968,364
Tax Rate
17.17%
18.61%
17.39%
NOPAT
1,382,767,678
1,147,091,102
1,002,105,835
Net income
1,083,315,886
26.31%
857,691,298
7.47%
798,056,210
102.76%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,200,751,000
BB yield
-5.58%
Debt
Debt current
465,594,047
1,531,935,793
1,281,047,076
Long-term debt
1,167,128,195
659,041,798
1,643,128,450
Deferred revenue
535,980,249
394,731,924
Other long-term liabilities
49,743,886
1,680,447,195
574,100,860
Net debt
1,152,635,489
87,266,424
1,958,494,868
Cash flow
Cash from operating activities
1,659,255,403
1,666,228,521
953,047,810
CAPEX
(1,303,573,258)
(995,070,662)
(1,009,225,611)
Cash from investing activities
(1,243,776,304)
(1,566,305,450)
(3,106,477,133)
Cash from financing activities
(433,788,285)
(635,049,948)
3,000,080,260
FCF
(255,914,677)
8,745,810
(493,446,232)
Balance
Cash
1,331,288,792
2,056,275,689
3,193,537,267
Long term investments
(851,202,039)
47,435,477
(2,227,856,608)
Excess cash
252,720,645
1,918,981,728
815,615,899
Stockholders' equity
5,264,543,620
4,181,427,801
3,323,536,436
Invested Capital
12,723,919,029
11,501,290,457
11,428,425,542
ROIC
11.42%
10.01%
13.06%
ROCE
11.97%
10.50%
9.01%
EV
Common stock shares outstanding
71,170
71,174
69,810
Price
949,000.00
24.87%
760,000.00
-7.43%
821,000.00
-8.00%
Market cap
67,540,492,279
24.86%
54,092,240,000
-5.62%
57,313,741,533
-3.96%
EV
68,693,127,768
54,179,706,491
59,274,409,795
EBITDA
2,268,604,562
1,899,168,730
1,521,338,520
EV/EBITDA
30.28
28.53
38.96
Interest
50,057,300
81,596,401
64,064,346
Interest/NOPBT
3.00%
5.79%
5.28%